Revolution Medicines

Yahoo Finance • 4 days ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 9 days ago

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

Revolution Medicines, Inc. REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the firs... Full story

Yahoo Finance • 2 months ago

Revolution Medicines outlines multiple Phase III trial launches and commercial buildout amid increased R&D investment

Earnings Call Insights: Revolution Medicines (RVMD) Q3 2025 MANAGEMENT VIEW * CEO Mark Goldsmith opened the call highlighting the company's ongoing commitment to “revolutionizing treatment for patients with RAS-addicted cancers through... Full story

Yahoo Finance • 2 months ago

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinica... Full story

Yahoo Finance • 2 months ago

Boeing upgraded, Charter downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Freedom Capital upgraded Boeing (BA) to... Full story

Yahoo Finance • 2 months ago

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will... Full story

Yahoo Finance • 2 months ago

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clini... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: Oracle, AST SpaceMobile, Revolution Medicines and more

Check out the companies making the biggest moves midday: AppFolio — The cloud-based business software provider climbed 7% after an upgrade to overweight from equal weight at KeyBanc, with a 12-month price target of $285, according to FactS... Full story

Yahoo Finance • 2 months ago

Achieve, Disc, Revolution among winners of initial FDA national priority vouchers

[US Food and Drug Administration (FDA)] Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]), Disc Medicine (NASDAQ:IRON [https://seekingalpha.com/symbol/IRON]), and Revolution Medicines (NASDAQ:RVMD [https://seeking... Full story

Yahoo Finance • 2 months ago

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S.... Full story

Yahoo Finance • 3 months ago

SA Asks: What's the most attractive biotech stock right now?

[Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21 What's the most attractive biotech stock right now for investors? Seeking Alpha analysts ONeil Trader [https://seekingalpha.com/autho... Full story

Yahoo Finance • 3 months ago

Revolution Medicines, Inc. (RVMD) Insider Sells Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) is among the most promising biotech stocks to buy according to hedge funds. On September 24, 2025, General Counsel and Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), Jeff Cislini, offloaded 1,... Full story

Yahoo Finance • 3 months ago

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointm... Full story

Yahoo Finance • 3 months ago

These 2 Stocks Could Be Prime Takeover Targets, According to Analysts

What began as a cautious ride earlier in the year has swelled into a full-blown bull market. The S&P 500 has climbed 14% in 2025, while the NASDAQ, lifted by the AI boom, has surged 17%. Elevate Your Investing Strategy: Take advantage of... Full story

Yahoo Finance • 4 months ago

Stocks making the biggest moves midday: Delta Air Lines, Revolution Medicines, Centene & more

Check out the companies making the biggest moves midday: Revolution Medicines — The biotech stock rallied 13% on the release of positive trial data for daraxonrasib, a drug aimed at treating pancreatic cancer. The company plans to begin a... Full story

Yahoo Finance • 4 months ago

Stocks Climb as US Labor Market Weakness Bolsters Fed Rate Cut Expectations

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.22%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • 4 months ago

Revolution Medicines rises on daraxonrasib data that supports phase 3 program

[Human Pancreatic Cancer] wildpixel * Revolution Medicines (NASDAQ:RVMD [https://seekingalpha.com/symbol/RVMD]) said that new clinical results from several phase 1 clinical trials support moving daraxonrasib into a phase 3 program for f... Full story

Yahoo Finance • 4 months ago

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial clinical results for daraxonrasib monotherap... Full story

Yahoo Finance • 4 months ago

Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the most promising future stocks according to Wall Street analysts. On August 18, Piper Sandler initiated coverage of Revolution Medicines, Inc. (NASDAQ:RVMD) with an Overweight rating and... Full story

Yahoo Finance • 4 months ago

Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 11 Best Short Squeeze Stocks to Buy Now. Following mixed results in the clinical trial of Ivonescimab, the company entered a new clinical collaboration with Revolution Medicines.Summit... Full story